Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications

Carling, Ulrik; Dorenberg, Eric; Haugvik, Sven-Petter; Eide, Nils; Berntzen, Dag Tallak Kjærsdalen; Edwin, Bjørn; Dueland, Svein; Røsok, Bård I.

doi:10.1007/s00270-015-1093-4

Cited by 31 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carling et al . [ 23 ] treated 14 patients with DEBIRI TACE and the median overall survival in this study was 9,4 months. They suggested that there was no significantly different impact on survival to other chemoembolization techniques.…”

Section: Discussionmentioning

confidence: 91%

Long-term survival in a patient with unresectable liver metastases from uveal melanoma treated with transarterial chemoembolization with irinotecan eluting beads – case report and review of literature

Stanisławska

Stadnik

Nawrocki

et al. 2017

View full text Add to dashboard Cite

IntroductionTreatment of unresectable liver metastases (LM) from uveal melanoma (UM) remains a major clinical challenge. Systemic chemotherapy and chemoimmunotherapy regimens extrapolated from cutaneous melanoma are considered to be ineffective in therapy of metastases from uveal melanoma. Studies suggest that the progression of hepatic metastases rather than the primary tumor or metastases in other organs determines survival.Case reportWe report a case of transarterial chemoembolization of 57-year-old man diagnosed with unresectable liver metastases from uveal melanoma with irinotecan eluting beads. Therapy resulted in long progression free survival and overall survival, 41 months and 45 months after diagnosis of metastatic disease respectively. Patient did not experience any major side effects of the therapy. Follow-up CTs indicate stable disease in mRECIST criteria and partial response in CHOI criteria.ConclusionsTransarterial chemoembolization with drug eluting beads loaded with irinotecan may be an effective treatment of unresectable liver metastases from uveal melanoma.

show abstract

Section: Discussionmentioning

confidence: 91%

Long-term survival in a patient with unresectable liver metastases from uveal melanoma treated with transarterial chemoembolization with irinotecan eluting beads – case report and review of literature

Stanisławska

Stadnik

Nawrocki

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Carling et al compared intra-arterial chemoembolization with 100 to 300 µm DEBs loaded with irinotecan (DEBIRI; n ¼ 14) to IV infusion of dacarbazine (n ¼ 14). 32 Pain and stasis are common after DEBIRI, and the intended irinotecan dose could not be delivered in half of the patients in this study. After treatment with DEBIRI, 64% (9/14) of patients experienced major complications, including liver dysfunction in 29% (4/14) and death in 7% (1/14).…”

Section: Drug-eluting Beadsmentioning

confidence: 87%

Making the Case: Intra-arterial Therapy for Less Common Metastases

Gordon

Uddin

Riaz

et al. 2017

Semin intervent Radiol

View full text Add to dashboard Cite

Intra-arterial therapies have high antitumor activity for both primary and secondary hepatic malignancies. Selective infusions allow increased delivery of cytoreductive therapy to the tumor bed while sparing the normal hepatic parenchyma. These therapies are now often applied in the outpatient setting or with short overnight hospital stays and have a growing role in the treatment of liver-dominant disease from metastatic colorectal cancer and from neuroendocrine tumors. Less commonly, intra-arterial therapies are applied to treat secondary hepatic malignancies from breast cancer, melanoma, pancreatic adenocarcinoma, and soft-tissue sarcomas. The available data are limited and generally retrospective observational cohort series of single institutions. The purpose of this article is to summarize the recent literature on outcomes for intra-arterial therapy in nonsurgical patients. Multi-institutional registries and prospective data are greatly needed, as intra-arterial therapies are increasingly applied in these patients to stop progression of chemorefractory tumors.

show abstract

“…TACE showed better results, with a median survival of 16.5 vs 12.2 months, while TACE did not result in any high-grade toxicities [33]. Chemoembolization using DEB-TACE in 14 patients with liver metastases from melanoma resulted in an OS of 9.4 months, and major complications including one death were reported in 12 cases [34].…”

Section: Available Literaturementioning

confidence: 99%

Locoregional ablative treatment of melanoma metastases

Putzer

Schullian

Bale

2019

International Journal of Hyperthermia

View full text Add to dashboard Cite

Standard treatment of melanoma has been evolving rapidly over the last decade, with novel treatment approaches improving therapeutic outcome not only in early-stage disease but also in advanced stage metastatic patients. Despite the improvement of systemic therapy outcomes, the current treatment guidelines reflect the fact that locoregional treatment approaches can be beneficial in patients suffering from oligometastatic disease. Minimally invasive ablation techniques have been established as a therapeutic cornerstone in the management of liver tumors, representing a local curative, relatively low-risk procedure. Depending on the size and location of metastatic disease, and on the applied ablation and guidance technique, ablative treatment approaches are effective to treat metastases in solid organs such as the liver or lungs, effectively covering the entire tumor with the ablation zone including a safety margin (A0 ablation in analogy to R0 resection). However, only retrospective data and case reports on locoregional treatment of melanoma metastases are available up to now, and prospective evaluation of this therapeutic approach is warranted to evaluate the beneficial role in the treatment of metastatic melanoma patients.

show abstract

Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications

Cited by 31 publications

References 34 publications

Long-term survival in a patient with unresectable liver metastases from uveal melanoma treated with transarterial chemoembolization with irinotecan eluting beads – case report and review of literature

Long-term survival in a patient with unresectable liver metastases from uveal melanoma treated with transarterial chemoembolization with irinotecan eluting beads – case report and review of literature

Making the Case: Intra-arterial Therapy for Less Common Metastases

Locoregional ablative treatment of melanoma metastases

Contact Info

Product

Resources

About